Last reviewed · How we verify
Salmonella Typhi
At a glance
| Generic name | Salmonella Typhi |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Acetylcholine Release Inhibitor [EPC] |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Inflammatory Challenge and Fear (PHASE1)
- Trivalent Salmonella Conjugate Vaccine (TSCV) (PHASE2)
- Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine (PHASE1)
- ZyVac-TCV Bangladesh Study (PHASE3)
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults (PHASE1)
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmonella Typhi CI brief — competitive landscape report
- Salmonella Typhi updates RSS · CI watch RSS
- University of Oxford portfolio CI